文献速递细菌感染、耐药与抗菌药物

1998-2016年英国牛津郡大肠埃希菌血流感染、尿路感染及抗生素敏感性趋势:基于电子健康记录的研究

Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records.
PubMed 文献 · Lancet Infect Dis · 2018-08-17

该观察性研究利用牛津郡研究数据库链接微生物学与医院电子健康记录,分析1998年1月1日至2016年12月31日共5706例大肠埃希菌血流感染和228376例大肠埃希菌尿路感染。结果显示血流感染总体发病率逐年上升(aIRR 1.06,95%CI 1.05-1.06),主要由社区相关病例驱动,社区和准社区病例aIRR分别为1.10(95%CI 1.07-1.13)和1.08(95%CI 1.07-1.10);30天死亡率在院内感染组下降(调整RR 0.98,95%CI 0.96-1.00),其他组保持稳定;社区中产超广谱β-内酰胺酶(ESBL)耐药菌株增加,作者建议关注初级保健机构中高阿莫西林/克拉维酸使用。

要点

  • 大肠埃希菌血流感染总体发病率逐年上升(aIRR 1.06,95%CI 1.05-1.06),主要由社区和准社区病例驱动。
  • 2016年515例血流感染中212例(41%)对阿莫西林/克拉维酸耐药,13792例尿路感染中3921例(28%)耐药。
  • 30天死亡率在院内感染组下降(调整RR 0.98,95%CI 0.96-1.00),其他组稳定,但所有组死亡率仍达14-25%。

核心结论

  • 牛津郡大肠埃希菌血流感染增加主要与社区相关,且阿莫西林/克拉维酸耐药普遍,但死亡率几乎无变化。
  • 作者认为聚焦初级保健机构(尤其高阿莫西林/克拉维酸使用机构)可能有效降低耐药大肠埃希菌血流感染发病率。

研究设计与样本

  • 观察性研究,利用牛津郡研究数据库(IORD)链接匿名微生物学数据与医院电子健康记录。
  • 纳入1998年1月1日至2016年12月31日期间所有大肠埃希菌血流感染和尿路感染数据。
  • 采用负二项回归模型分析微生物学、临床和医疗暴露风险因素。

主要发现

  • 1998-2016年共发生5706例大肠埃希菌血流感染(5215例患者)和228376例大肠埃希菌尿路感染(137075例患者)。
  • 血流感染中院内感染1365例(24%)、准院内感染1132例(20%)、准社区感染1346例(24%)、社区感染1863例(33%)。
  • 总体发病率逐年上升(aIRR 1.06,95%CI 1.05-1.06);社区病例aIRR 1.10(95%CI 1.07-1.13,p<0.0001),准社区病例aIRR 1.08(95%CI 1.07-1.10,p<0.0001)。
  • 2016年515例血流感染中212例(41%)对阿莫西林/克拉维酸耐药,13792例尿路感染中3921例(28%)耐药。
  • 30天死亡率:院内感染组调整RR 0.98(95%CI 0.96-1.00,p=0.03);准院内感染组调整RR 0.98(95%CI 0.95-1.00,p=0.06);准社区组调整RR 0.99(95%CI 0.96-1.01,p=0.32);社区组调整RR 0.99(95%CI 0.96-1.01,p=0.21);所有组死亡率达14-25%。

关键数值与推荐

  • 阿莫西林/克拉维酸耐药大肠埃希菌血流感染在所有组中增加(每年增加11-18%,显著快于敏感菌株,pheterogeneity<0.0001)。
  • 阿莫西林/克拉维酸耐药大肠埃希菌尿路感染每年增加14-29%(pheterogeneity<0.0001)。
  • 初级保健机构上一年阿莫西林/克拉维酸使用与下一年社区耐药大肠埃希菌尿路感染增加相关(p=0.003)。

临床怎么用

  • 作者认为聚焦初级保健机构,尤其是阿莫西林/克拉维酸高使用机构,可能有效降低耐药大肠埃希菌血流感染发病率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Escherichia coli bloodstream infections are increasing in the UK and internationally. The evidence base to guide interventions against this major public health concern is small. We aimed to investigate possible drivers of changes in the incidence of E coli bloodstream infection and antibiotic susceptibilities in Oxfordshire, UK, over the past two decades, while stratifying for time since hospital exposure. METHODS: In this observational study, we used all available data on E coli bloodstream infections and E coli urinary tract infections (UTIs) from one UK region (Oxfordshire) using anonymised linked microbiological data and hospital electronic health records from the Infections in Oxfordshire Research Database (IORD). We estimated the incidence of infections across a two decade period and the annual incidence rate ratio (aIRR) in 2016. We modelled the data using negative binomial regression on the basis of microbiological, clinical, and health-care-exposure risk factors. We investigated infection severity, 30-day all-cause mortality, and community and hospital amoxicillin plus clavulanic acid (co-amoxiclav) use to estimate changes in bacterial virulence and the effect of antimicrobial resistance on incidence. FINDINGS: From Jan 1, 1998, to Dec 31, 2016, 5706 E coli bloodstream infections occurred in 5215 patients, and 228 376 E coli UTIs occurred in 137 075 patients. 1365 (24%) E coli bloodstream infections were nosocomial (onset >48 h after hospital admission), 1132 (20%) were quasi-nosocomial (≤30 days after discharge), 1346 (24%) were quasi-community (31-365 days after discharge), and 1863 (33%) were community (>365 days after hospital discharge). The overall incidence increased year on year (aIRR 1·06, 95% CI 1·05-1·06). In 2016, 212 (41%) of 515 E coli bloodstream infections and 3921 (28%) of 13 792 E coli UTIs were co-amoxiclav resistant. Increases in E coli bloodstream infections were driven by increases in community (aIRR 1·10, 95% CI 1·07-1·13; p<0·0001) and quasi-community (aIRR 1·08, 1·07-1·10; p<0·0001) cases. 30-day mortality associated with E coli bloodstream infection decreased over time in the nosocomial (adjusted rate ratio [RR] 0·98, 95% CI 0·96-1·00; p=0·03) group, and remained stable in the quasi-nosocomial (adjusted RR 0·98, 0·95-1·00; p=0·06), quasi-community (adjusted RR 0·99, 0·96-1·01; p=0·32), and community (adjusted RR 0·99, 0·96-1·01; p=0·21) groups. Mortality was, however, substantial at 14-25% across all hospital-exposure groups. Co-amoxiclav-resistant E coli bloodstream infections increased in all groups across the study period (by 11-18% per year, significantly faster than co-amoxiclav-susceptible E coli bloodstream infections; pheterogeneity<0·0001), as did co-amoxiclav-resistant E coli UTIs (by 14-29% per year; pheterogeneity<0·0001). Previous year co-amoxiclav use in primary-care facilities was associated with increased subsequent year community co-amoxiclav-resistant E coli UTIs (p=0·003). INTERPRETATION: Increases in E coli bloodstream infections in Oxfordshire are primarily community associated, with substantial co-amoxiclav resistance; nevertheless, we found little or no change in mortality. Focusing interventions on primary care facilities, particularly those with high co-amoxiclav use, could be effective in reducing the incidence of co-amoxiclav-resistant E coli bloodstream infections, in this region and more generally. FUNDING: National Institute for Health Research.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Vihta KD, Stoesser N, Llewelyn MJ, et al. Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records. Lancet Infect Dis. 2018. PMID: 30126643. doi:10.1016/S1473-3099(18)30353-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。